Hemodynamic actions of systemically injected pituitary adenylate cyclase activating polypeptide-27 in the rat

作者: Erin J Whalen , Alan Kim Johnson , Stephen J Lewis

DOI: 10.1016/S0014-2999(98)00852-8

关键词: Sympathetic nervous systemChlorisondaminePropranololNitrovasodilatorNorepinephrine secretionInternal medicineBaroreceptorCatecholamineEndocrinologyVasodilationChemistry

摘要: The aims of this study were (1) to characterize the hemodynamic mechanisms underlying hypotensive effects pituitary adenylate cyclase activating polypeptide-27 (PACAP-27 0.1-2.0 nmol/kg, i.v.) in pentobarbital-anesthetized rats, and (2) determine roles autonomic nervous system, adrenal catecholamines endothelium-derived nitric oxide (NO) expression PACAP-27-mediated on function. PACAP-27 produced dose-dependent decreases mean arterial blood pressure hindquarter mesenteric vascular resistances saline-treated rats. also pronounced falls rats treated with ganglion blocker, chlorisondamine (5 mg/kg, i.v.). vasodilator actions not attenuated by beta-adrenoceptor antagonist, propranolol (1 i.v.), or NO synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME 50 micromol/kg, increases heart rate whereas response nitrovasodilator, sodium nitroprusside (10 microg/kg, was associated a minimal tachycardia. PACAP-27-induced tachycardia unaffected chlorisondamine, but virtually abolished propranolol. These results suggest that are due microcirculation rather than release vasodilation may involve NO. produces directly releasing norepinephrine from cardiac sympathetic nerve terminals direct baroreceptor reflex-mediated activity.

参考文章(28)
John B. Warren, Amanda J. Wilson, Rashpal K. Loi, Margaret L. Coughlan, Opposing roles of cyclic AMP in the vascular control of edema formation. The FASEB Journal. ,vol. 7, pp. 1394- 1400 ,(1993) , 10.1096/FASEBJ.7.14.7693536
S J Lewis, C Barres, H J Jacob, H Ohta, M J Brody, Cardiovascular effects of the N-methyl-D-aspartate receptor antagonist MK-801 in conscious rats. Hypertension. ,vol. 13, pp. 759- 765 ,(1989) , 10.1161/01.HYP.13.6.759
J.B. Warren, S.W. Larkin, M. Coughlan, R. Kajekar, T.J. Williams, Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo British Journal of Pharmacology. ,vol. 106, pp. 331- 334 ,(1992) , 10.1111/J.1476-5381.1992.TB14336.X
Atsuro Miyata, Akira Arimura, Raymond R. Dahl, Naoto Minamino, Akira Uehara, Lun Jiang, Michael D. Culler, David H. Coy, Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells Biochemical and Biophysical Research Communications. ,vol. 164, pp. 567- 574 ,(1989) , 10.1016/0006-291X(89)91757-9
KATALIN KÖVES, AKIRA ARIMURA, ANIKÓ SOMOGYVÁRI-VIGH, SÁNDOR VIGH, JIM MILLER, Immunohistochemical demonstration of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, in the ovine hypothalamus. Endocrinology. ,vol. 127, pp. 264- 271 ,(1990) , 10.1210/ENDO-127-1-264
John B. Warren, Louise E. Donnelly, Seamus Cullen, Blair E. Robertson, Mohammad A. Ghatei, Stephen R. Bloom, John MacDermot, Pituitary adenylate cyclase-activating polypeptide: a novel, long-lasting, endothelium-independent vasorelaxant. European Journal of Pharmacology. ,vol. 197, pp. 131- 134 ,(1991) , 10.1016/0014-2999(91)90511-N
Rolf Uddman, Anders Luts, Akira Arimura, Frank Sundler, Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract. Cell and Tissue Research. ,vol. 265, pp. 197- 201 ,(1991) , 10.1007/BF00318155